NCT03159143 - Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2004

Primary Completion Date

June 2, 2009

Study Completion Date

December 2, 2009

Conditions

Metastatic Transitional Cell Cancer of the Urothelial Tract

Interventions

DRUG

Docetaxel

Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m\^2.

DRUG

Oxaliplatin

Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m\^2

Trial Locations (1)

15232

University of Pittsburgh Cancer Institute, Pittsburgh